We are happy to share a significant milestone for one of our portfolio companies, VERIGRAFT. The biotech innovator has announced a committed capital contribution of SEK 110 million from an existing long-term shareholder, marking a pivotal moment in their journey to redefine transplant medicine.
This substantial investment serves as a powerful validation of VERIGRAFT’s personalized tissue technology and its strategic execution. For us at Sahlgrenska Science Park, seeing a company progress from early-stage development to the brink of large-scale international clinical trials is a testament to the strength of the life science ecosystem we strive to cultivate.
Scaling for global impact
The new funding is specifically earmarked to accelerate VERIGRAFT’s transition into its next clinical phase. This includes preparing for Phase II/III (pivotal) trials in both Europe and the United States—a rigorous stage that brings their personalized tissue-engineered veins (P-TEV) closer to the patients who need them most.
The investment will support:
Clinical Readiness: Infrastructure and execution for pivotal trials.
Regulatory Milestones: Navigating submission-related activities in global markets.
Manufacturing Excellence: Scaling CMC (Chemistry, Manufacturing, and Controls) capabilities.
A shared success
"This investment represents strong long-term conviction," says Petter Björquist, CEO of VERIGRAFT. It is exactly this kind of conviction that transforms Swedish innovation into global healthcare solutions.
As a science park with a visionary accelerator, Sahlgrenska Science Parks's goal is to provide the environment, networks, and support necessary for companies to reach "pivotal readiness." Seeing them secure the financial flexibility to execute their strategy with speed and discipline is a win for the entire Sahlgrenska Science Park community.
We look forward to following VERIGRAFT as they enter this next chapter of clinical validation and continue to pioneer the future of regenerative medicine.